Evidence map›Paper›PMID 33611726›Full record

ArticleNeurochemical research2021

A Novel Pharmacological Protective Role for Safranal in an Animal Model of Huntington's Disease.

Ahmad Fotoohi, Mohammad Raman Moloudi, Saed Hosseini, Kambiz Hassanzadeh, Marco Feligioni, Esmael Izadpanah

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Pharmacological effects of Safranal: An updated review.Iranian journal of basic medical sciences · 2023
    Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ahmad Fotoohi *Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Mohammad Raman Moloudi *Neurosciences Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Saed HosseiniStudent Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Kambiz HassanzadehCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Kudistan Province, Pasdaran Avenue, Sanandaj, Iran.
Marco FeligioniLaboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, 00161, Rome, Italy. m.feligioni@ebri.it.ORCID http://orcid.org/0000-0001-7070-9662
Esmael IzadpanahCellular and Molecular Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Kudistan Province, Pasdaran Avenue, Sanandaj, Iran. eizadpanah2000@muk.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a progressive, neurodegenerative and inherited disease and recent years have witnessed the understanding of the cellular and molecular mechanisms related to HD. Safranal, an organic compound isolated from saffron, has been reported to have anti-apoptotic, anti-inflammatory and antioxidant activity and has studied in chronic and neurodegenerative disease. Therefore, this study was aimed to investigate the effect of safranal on 3-NP induced locomotor activity and biochemical alterations in rats. To this aim, 40 male Wistar rats weighting 250-300 g were divided into 5 groups (n = 8) including sham, 3-NP group (10 mg/kg) as control and treatment groups (3-NP + safranal 0.75, 1.5 and 3 mg/kg) in two weeks duration of treatment. Behavioral/movement assessments in addition to oxidant/antioxidant markers in rat cortex and striatum were evaluated in control and treatment groups. Here, we found that safranal significantly alleviated 3-NP-induced changes of body weight, rotarod activity, number of vacuous chewing movements (VCMs), and locomotor activity. In addition, brain tissue assessments in cortex and striatum revealed that safranal could prevent the elevation of nitrite and malondialdehyde (MDA) levels as well as decrease of superoxide dismutase (SOD), catalase activity and glutathione (GSH) induced by 3-NP. In conclusion our results showed that safranal prevented the motor dysfunction induced by 3-NP in animal model of Huntington's disease. This effect might be due to its modulating effect on oxidants-antioxidant balance.

Indexed as

AnimalsAntioxidantsBehavior, AnimalBody WeightCatalaseCerebral CortexCyclohexenesGlutathioneHuntington DiseaseLocomotionMaleMalondialdehydeMasticationNeuroprotective AgentsNitro CompoundsPropionates3-nitropropionic acidAntioxidantsCatalaseCyclohexenesGlutathioneMalondialdehydeNeuroprotective AgentsNitro CompoundsPropionatessafranalSuperoxide DismutaseTerpenes3-nitropropionic acidHuntington’s diseaseLocomotor activitySaffron

Identifiers

PMID33611726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.